Peer-reviewed veterinary case report
Inhaled ciclesonide helps treat severe asthma in horses
By Pirie, Robert Scott et al.·Published in Equine veterinary journal·2021·Royal (Dick) School of Veterinary Studies, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Inhaled ciclesonide is efficacious and well tolerated in the treatment of severe equine asthma in a large prospective European clinical trial.
- Species:
- horse
Plain-English summary
A group of 224 horses with severe asthma were treated with an inhaled medication called ciclesonide to see if it could help reduce their breathing problems. After 10 days, about 73% of the horses that received ciclesonide showed significant improvement in their symptoms, compared to only 43% in the group that received a placebo. The treatment was generally well tolerated, with few side effects noted. This suggests that inhaled ciclesonide could be an effective option for managing severe asthma in horses.
People also search for: horse asthma treatment · ciclesonide for horses · severe equine asthma symptoms
Abstract
BACKGROUND: Ciclesonide is a glucocorticoid prodrug, already registered for human use. Due to its mode of action and inhaled route of administration, it was considered an appropriate treatment option for horses with severe equine asthma. Although the efficacy of inhaled ciclesonide has been demonstrated in horses with asthma exacerbations under controlled mouldy hay challenge conditions, it has not yet been reported under field conditions. OBJECTIVES: To assess the effectiveness and safety of inhaled ciclesonide for the treatment of severe equine asthma. STUDY DESIGN: Prospective, multicentre, placebo-controlled, randomised, double-blinded study. METHODS: Two-hundred and twenty-four client-owned horses with severe equine asthma were randomised (1:1 ratio) to receive either ciclesonide inhalation (343 µg/actuation) solution or placebo (0 µg/actuation). Treatments (placebo or ciclesonide) were administered with a nonpressurised Soft Mist™ inhaler specifically developed for horses (AservoEquiHaler) at doses of 8 actuations twice daily for the first 5 days and 12 actuations once daily for the following 5 days. Primary outcome was a success/failure analysis with the a priori definition of treatment success as a 30% or greater reduction in weighted clinical score (WCS) between Day 0 and Day 10 (±1). RESULTS: The treatment success rate (as defined above) in ciclesonide-treated horses was 73.4% (80/109) after 10 (±1) days of treatment, being significantly higher than in the placebo group with 43.2% (48/111; P < 0.0001). Few systemic and local adverse events of ciclesonide were observed. MAIN LIMITATIONS: The severity of clinical signs of severe equine asthma varies over time; despite the prohibition of environmental management changes during the study, a placebo effect was also identified. This potentially contributed, in part, to the clinical improvement observed in the ciclesonide-treated group. CONCLUSIONS: Ciclesonide inhalation solution administered by the AservoEquiHalereffectively reduced severity of clinical signs in a majority of horses with severe equine asthma and was well tolerated.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33403727/